iOnctura Company
iOnctura is a biopharmaceutical company that focuses on developing novel therapeutics to modulate immunosuppression in the tumor microenvironment. The company aims to improve current immune checkpoint therapies by developing drugs that can optimize clinical outcomes when combined with checkpoint inhibition. iOnctura has partnerships with Merck and Cancer Research Technology, which have helped establish a pipeline of preclinical molecules to advance towards the clinic in combination with immuno-oncology assets from Merck. The company is supported by a world-renowned scientific advisory board and has access to CRT's drug discovery labs and network of academic collaborators. iOnctura is dedicated to delivering innovative cancer treatments to patients with unmet medical needs.
